Dr Tony Mok talks to ecancer at the 2012 ESMO meeting in Vienna about a randomised phase III study that looked at sorafnib in combination with the best supportive care in selected populations as third and fourth line therapy.
Overall the MISSION study showed only slight improvement in progression free survival in patients with non-small cell lung cancer. Ultimately the results were deemed as negative.
Although negative in terms of survival, Dr Mok expressed that the study provided information on small populations that had better survival compared to populations with EGF 1 mutation. Also, the study showed results that concluded that KRAS is not an effective biomarker for sorafnib.
Filming supported by Amgen